Mitomycin A

  • Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-6,8a-dimethoxy-5-methyl-, (1aS,8S,8aR,8bS)-
Formula
C16H19N3O6
Structure
Description
Red-violet crystals from acetone + carbon tetrachloride.
Uses
DNA alkylating cross-linking agent mitomycins.

Registry Numbers and Inventories.
CAS
4055-39-4
RTECS
CN1050000
RTECS class
Mutagen
Beilstein/Gmelin
56946
Beilstein Reference
4-25-00-00516

Properties.
Formula
C16H19N3O6
Formula mass
349.38
Melting point, °C
160
Solubility in water
Insoluble
pKa/pKb
9.19 (pKb)

Hazards and Protection.
Storage
Keep in a cool, dry, dark location in a tightly sealed container or cylinder. Keep away from incompatible materials, ignition sources and untrained individuals. Secure and label area. Protect containers/cylinders from physical damage.
Handling
All chemicals should be considered hazardous. Avoid direct physical contact. Use appropriate, approved safety equipment. Untrained individuals should not handle this chemical or its container. Handling should occur in a chemical fume hood.
Protection
Chemical splash goggles in compliance with OSHA regulations are advised; however, OSHA regulations also permit other type safety glasses. Whre chemical resistant gloves. To prevent repeated or prolonged skin contact, wear impervious clothing and boots.
Respirators
Use NIOSH/MSHA approved respirator appropriate for exposure of concern.
Small spills/leaks
Evacuate area and ventilate. Wear protective equipment. If required, use an inert absrobent. Sweep up and place in an appropriate container for disposal. Wash contaminated surfaces.
Stability
No data.
Incompatibilities
Strong oxidizing agents.

Fire.
Fire fighting
Wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Use agent most appropriate to extinguish fire.

Health.
Exposure effects
With therapeutic use - 1. Fever may occur with therapy. With therapeutic use - 1. Confusion, drowsiness, fatigue, lethargy, and weakness can occur with therapy. Teratogenic effects, effects in pregnancy, effects during breast feeding and paternal effects have been observed.
   Eyes
Blurred vision may occur during therapy. Ocular instillation has resulted in inflammation of the eye, ocular degeneration and glaucoma with prolonged use.

First aid
 
   Ingestion
Mitomycin is only available in an injectable dosage form intended for intravenous use. The probability of oral exposure is low. Treatment should include recommendations listed in the parenteral exposure section where applicable.
   Inhalation
Move patient to fresh air. Monitor for respiratory distress. If cough or difficulty breathing develops, evaluate for respiratory tract irritation, bronchitis, or pneumonitis. Administer oxygen and assist ventilation as required. Treat bronchospasm with beta2 agonist and corticosteroid aerosols.
   Skin
Remove contaminated clothing and wash exposed area thoroughly with soap and water. A physician should examine the area if irritation or pain persists. Supportive care is all that is required. Transfusions may be necessary during leukopenic phase. Monitor patient for signs/symptoms of bleeding or infection. Interstitial pneumonia may respond to corticosteroid therapy.
   Eyes
Irrigate exposed eyes with copious amounts of tepid water for at least 15 minutes. If irritation, pain, swelling, lacrimation, or photophobia persist, the patient should be seen in a health care facility.

Transport.